Letters Quadrivalent HPV vaccine

Wider cost benefits of vaccine

BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c4455 (Published 19 August 2010) Cite this as: BMJ 2010;341:c4455
  1. Colm O’Mahony, consultant in genitourinary medicine and HIV1,
  2. Peter Greenhouse2,
  3. Angela Robinson3,
  4. Chris Sonnex4
  1. 1Department of Sexual Health (GUM), Countess of Chester Hospital, Chester CH2 1UL
  2. 2Bristol Sexual Health Centre, Bristol BS2 0JD
  3. 3Mortimer Market Centre, London WC1E 6JB
  4. 4Addenbrooke’s Hospital, Cambridge CB2 2QQ
  1. colm.omahony{at}hotmail.co.uk

    The FUTURE Study Group’s results confirm the benefit to women of vaccinating against human papillomavirus (HPV) types 16 and 18 and emphasise the value of including HPV-6 and HPV-11 in any vaccine programme.1 HPV-6 and HPV-11 cause almost all condylomatas and a large proportion of cases of low grade vulval, vaginal, and cervical intraepithelial …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe